Novel drug shows promise in treating drug-resistant prostate cancerApril 8th, 2009 - 1:11 pm ICT by ANI
Washington, April 8 (ANI): An experimental drug for metastatic prostate cancer has shown considerable promise in early clinical trials by reducing signs of the disease in patients with drug-resistant cancer.
Of 30 men who received low doses of one the drugs in a multisite phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen (PSA) in their blood.
Phase III clinical trials are planned to evaluate the drug’s effect on survival in a large group of patients with metastatic prostate cancer.
The drugs are second-generation antiandrogen therapies that prevent male hormones from stimulating growth of prostate cancer cells.
The new compounds - manufactured by the pharmaceutical company Medivation and known as MDV3100 and RD162 - appear to work well even in prostate cells that have a heightened sensitivity to hormones.
That heightened sensitivity makes prostate cancer cells resistant to existing antiandrogen therapies.
The drugs were discovered in the laboratory of Howard Hughes Medical Institute investigator Charles Sawyers at Memorial Sloan-Kettering Cancer Center in collaboration with chemist Michael Jung at UCLA.
Sawyers’s team collaborated on the studies with researchers from the University of California Los Angeles, Oregon Health and Science University, University of Washington and Medivation.
He and his colleagues described the development of the drugs and initial testing in an article posted online April 9, 2009, in Science Express. (ANI)
- Experimental drug for advanced prostate cancer shows promise - Apr 15, 2010
- Genomic analysis of prostate cancer unveiled - Jun 26, 2010
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Pomegranate juice could be key to new cancer therapies - Dec 13, 2010
- Soy-based drug 'may stop prostate cancer spread' - Nov 09, 2010
- CT scan more effective in parallel breast and bone cancer detection - Sep 06, 2010
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- Scientists find new way to 'starve' cancer cells - Apr 05, 2011
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- Antibiotic used in meat, dairy industry slows prostate cancer growth - Dec 21, 2010
- New vitamin E treatment for prostate cancer - Oct 20, 2010
- Scientists stumble upon 'stop cancer' gene - Nov 16, 2011
- Target therapy 'boosts longevity in HER2-positive breast cancer patients' - Dec 12, 2009
- Cancer 'wonder drug' launched in Britain - Sep 21, 2011
Tags: charles sawyers, experimental drug, howard hughes medical, howard hughes medical institute, hughes medical institute, kettering cancer center, male hormones, medivation, memorial sloan kettering, memorial sloan kettering cancer center, michael jung, novel drug, prostate cancer, prostate cancer cells, prostate cells, prostate specific antigen, science express, sloan kettering cancer, sloan kettering cancer center, university of california los angeles